165 related articles for article (PubMed ID: 30509037)
1. The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures.
Kuzniewska B; Sadowski K; Urbanska K; Urbanska M; Kotulska K; Liszewska E; Grajkowska W; Jóźwiak S; Dziembowska M
Folia Neuropathol; 2018; 56(3):167-174. PubMed ID: 30509037
[TBL] [Abstract][Full Text] [Related]
2. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
3. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
Tang X; Angst G; Haas M; Yang F; Wang C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of the MMP/TIMP Proteolytic System in Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex: Modulation of MMP by MicroRNA-320d In Vitro.
Bongaarts A; de Jong JM; Broekaart DWM; van Scheppingen J; Anink JJ; Mijnsbergen C; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Hainfellner JA; Feucht M; Borkowska J; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Scicluna BP; Schouten-van Meeteren AYN; van Vliet EA; Mühlebner A; Mills JD; Aronica E
J Neuropathol Exp Neurol; 2020 Jul; 79(7):777-790. PubMed ID: 32472129
[TBL] [Abstract][Full Text] [Related]
5. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
7. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
8. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
10. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
12. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Curran MP
Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
[TBL] [Abstract][Full Text] [Related]
13. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
14. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications.
Trelinska J; Fendler W; Dachowska I; Kotulska K; Jozwiak S; Antosik K; Gnys P; Borowiec M; Mlynarski W
Orphanet J Rare Dis; 2016 Sep; 11(1):129. PubMed ID: 27680012
[TBL] [Abstract][Full Text] [Related]
15. Subependymal giant-cell astrocytomas in the absence of tuberous sclerosis.
Reynolds RA; Aum DJ; Gonzalez-Gomez I; Wong M; Roberts K; Dahiya S; Rodriguez LF; Roland JL; Smyth MD
J Neurosurg Pediatr; 2023 Sep; 32(3):351-357. PubMed ID: 37327147
[TBL] [Abstract][Full Text] [Related]
16. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.
Lam C; Bouffet E; Tabori U; Mabbott D; Taylor M; Bartels U
Pediatr Blood Cancer; 2010 Mar; 54(3):476-9. PubMed ID: 19856393
[TBL] [Abstract][Full Text] [Related]
18. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
19. An update on the central nervous system manifestations of tuberous sclerosis complex.
Cotter JA
Acta Neuropathol; 2020 Apr; 139(4):613-624. PubMed ID: 30976976
[TBL] [Abstract][Full Text] [Related]
20. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]